Three All-Oral Shortened Regimens Noninferior for Rifampin-Resistant TB
Noninferior efficacy seen for three all-oral regimens compared with standard therapy in intention-to-treat, per-protocol populations
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
Adding nivolumab to neoadjuvant chemotherapy significantly increases pathological complete response rates
FDA Approves Symbravo for Acute Treatment of Migraine in Adults
Symbravo can rapidly eliminate migraine pain within two hours, with efficacy sustained through 24 and 48 hours, across migraine pain severity
Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC
Significant and clinically relevant improvement seen in objective response rate with encorafenib + cetuximab plus mFOLFOX6
Four in 10 Patients Receiving Chemo Develop Chronic Painful Neuropathy
Among patients with chemotherapy-induced peripheral neuropathy, those treated with platinum-based agents, taxanes had highest prevalence
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
Approval is targeted for patients with HER2-low or HER2-ultralow metastatic breast cancer with disease progression after endocrine therapy
Large Decrease Seen in Antidepressant Use During Pregnancy
No increase reported in psychotherapy claims during pregnancy; medication fills returned to prepregancy levels within one month after birth
FDA Approves Datroway for HR-Positive, HER2-Negative Breast Cancer
Approval is for those who have had prior therapy for unresectable or metastatic disease
Daily, Long-Term Aspirin Use Reduces Colorectal Cancer Recurrence
Findings seen for patients with somatic alterations in the PI3K signaling pathway
